As long as you can maintain an uninterupted supply of the drugs I don't see anything wrong with switching. In my opinion this stuff isn't rocket science. You take the dope and hope. Of course it really helps to have a doctor who is willing to support you with procrit or neupogen should the need arise and that's what I would look for in a physician. I think that's key. Good luck. Mike
I switched a month into Tx. Not a good rapport with the doc at that practice.
I now am thinking about finding a doc that will extend Tx beyond 48 wks. present practice won't do it.
Vicki(beffud) here had lots of food fights with a nurse hatchet who I believe has been beamed up.
Switching doctors is probably just fine as long as you can find one that is qualified and one that you are comfortable with. However, it's a shame that you are forced to switch doctors if you are comfortable with your current doctor. As a last resort, you may want to make an appt for a conference with your doctor and indicate to him that if you do not get a better response from his staff that you will be forced to look for someone else that can be responsive to you. He may make some changes in his office that will not only benefit you, but anyone else following in your footsteps. On the other hand, if you really don't care one way or the other about the current doc, go ahead and switch.
I am so glad I found this site yesterday. I have heard so many things I did not know. One of my concerns was seeing another doctor. The doctor I have is nice but I was never given or told of some of the things I hear you talk about. I think maybe I will look into seeing another.
I do wonder if different meds are available in the United States then in Canada. I am in Ontario.
i am now switching drs too.i have an apt. with a possible new one next week. i felt like a number to my gastro. he only spends "2-4 min." with me at an average visit. he never does things like take my blood pressure, wiegh me, listen to my heart, look me over...he also is very put out by my questions and concerns. there are other important problems that have occured as well, like denying me my 12 pcr/rna to check evr. now i'm stuck without knowing if i truly cleared early or not. also if i have to miss an apt. i have to wait a whole month to be seen again. this can't be wise if they are truly interested in my blood tests. i hope the new GI will be more concerned about his patience.
i'm also hopeing all goes smoothly so tx is not interrupted at any cost. i hope i will get a qualified and experienced new dr. and not have any problems,with the flow of things or getting needed blood drugs etc...
make sure you have enough meds to cover yourself while finding a new dr. also, make sure your blood counts and schedual of apointments will not be interrupted. perhaps make a future apt. with your present dr. and then you can cancel it if you find a new one that you like. that way your back is covered. he doesn't need to know your looking arround until you find one you like, and your bases are covered. I PRAY YOU FIND A GOOD ONE. sandi
Because of posting limitations, I was forced to post this interesting article in this thread:
Proliferation of Polymerase Inhibitors and Other Tales From the HCV Crypt
By Tracy Swan
Building a Better Ribavirin
Liver disease has become increasingly prominent in the HAART era. Hepatitis C progresses more rapidly in HIV-positive people, and is more difficult to treat. More effective, less toxic treatments for the hepatitis C virus (HCV) are urgently needed. Tracy Swan prepared this HCV pipeline report exclusively for TAGline.
The current standard of care for hepatitis C involves six to twelve months of combination treatment with pegylated interferon alfa, injected weekly, and ribavirin, a nucleoside analogue taken orally every day. Unlike HIV, successful hepatitis C treatment can result in viral clearance. The main goal of treatment is a sustained virologic response, when HCV remains undetectable six months after completion of therapy. More than 85% of people who have achieved an sustained virologic response remain free of HCV five years after completion of therapy. Secondary goals of treatment include normalization of liver enzymes and improvement in liver inflammation and fibrosis.
Hepatitis C treatment only succeeds in about half of people with hepatitis C. Various factors influence treatment outcome, including HCV genotype and viral load, HIV status, race, age, and body weight. Data from three pivotal coinfection trials, ACTG A5071, ANRS HC02 (RIBAVIC) and Roche's APRICOT (AIDS Pegasys and Ribavirin International Co-Infection Trial) are expected later this month. Preliminary data from A5071 and RIBAVIC indicate that pegylated interferon appears to be more effective than non-pegylated interferon in coinfected patients after both 24 and 48 weeks of treatment, but the response rates remain lower than those reported in HCV monoinfection treatment trials.
Pegylated interferon and ribavirin have several serious side effects, including depression, anemia, and neutropenia. Some of these side effects overlap with symptoms of HIV disease and side effects of certain HIV medications. Potentially dangerous drug interactions between ribavirin and other nucleoside analogues -- notably ddI (Videx) and d4T (Zerit) -- have also been documented.
Coinfected people often experience severe side effects during HCV treatment, making adherence difficult. In HCV treatment trials -- where monitoring and management of side effects and adverse events is generally most vigilant -- drop-out rates have been high. In ANRS HC02, only 224 of an original 416 completed 48 weeks of treatment. Severe adverse events -- psychiatric side effects, sepsis, pneumonia, hepatic failure, acute pancreatitis and hyperlactatemia -- were reported among 23% of the pegylated interferon group, and 19% of the interferon group, and four people died during the study.
The suboptimal efficacy and tolerability of HCV therapy does not bode well for coinfected persons for whom HCV has become a major medical concern. Hepatitis C is prevalent among people with HIV in the United States and Europe. In the United States, approximately 25% of HIV-positive people are coinfected with hepatitis C. Among those who attribute their HIV to injection drug use, HCV is far more prevalent: as many as 90% are coinfected. HIV infection accelerates HCV disease progression, increasing the risk for developing cirrhosis, hepatocellular carcinoma, and liver failure. End-stage liver disease resulting from HCV coinfection has become a leading cause of death among HIV-positive people in the developed world.
Coinfected people and their clinicians must weigh current HCV treatment options against the immediacy of the need for treatment. Over the short term, until new therapies become available, researchers and clinicians are trying to optimize HCV treatment outcomes among coinfected people by various strategies, which include extending the duration of therapy by an additional six months, using growth factors instead of dose reductions to manage anemia from ribavirin and neutropenia from pegylated interferon, and using induction therapy with high-dose interferon. For virologic non-responders, researchers are exploring whether long-term maintenance therapy with low-dose pegylated interferon may prevent progression of liver disease.
Over the longer term, improvements in HCV treatment will require drugs with one or more of the following characteristics:
More effective -- increased likelihood of achieving a sustained virologic response, especially in people at high risk of disease progression (people with HIV, people with advanced fibrosis or cirrhosis)
Effective across all groups -- drugs that will work better in those who are less likely to respond to current therapies, such as African-Americans and people with HCV genotype 1
Effective as second-line therapies -- drugs that will work for those who did not respond to previous HCV therapy
Better tolerated -- therapies with fewer or more benign side effects
Beneficial to the liver -- drugs that halt or decrease liver inflammation and fibrosis progression, even in the absence of sustained virologic responses
High genetic barrier to resistance -- drugs that delay or prevent the emergence of drug-resistant virus
Easily administrated -- treatments that do not require injection or long-term (>1 year) course of treatment
Replacements for current therapy -- drugs that eliminate the need for interferon and/or ribavirin
While no single drug may meet all of these criteria, combinations of new drugs may ultimately bring dramatic improvements in the efficacy and tolerability of HCV treatment. As with HIV, combination treatment will remain the standard, since viral resistance to most single-drug therapy is likely. In the near future, any new drug will need to be used in combination with pegylated interferon (and, in some cases, ribavirin) until enough new agents are available for novel combinations.
The most exciting new antiviral treatments target HCV directly by inhibiting viral proteins such as the hepatitis C protease and polymerase enzymes. This approach parallels the development of antiretrovirals used in HIV treatment. Alternative forms of interferon and ribavirin, along with other immunomodulatory drugs, are also in development. However, strategies aimed at stimulating the immune system to fight HCV could in theory be less effective in people with impaired immune responses due to HIV infection.
A New Class of HCV Drugs: Serine Protease Inhibitors
Many companies have pursued drugs designed to inhibit the HCV serine protease enzyme, based on the success of protease inhibitors in HIV treatment. As with HIV, the hepatitis C virus encodes a protease enzyme essential for viral replication. However the HCV protease has proven a more difficult target due to the shape of the molecule. While many compounds have demonstrated antiviral efficacy in vitro, few have moved into human studies.
Early excitement was generated from proof-of-concept reports on Boehringer Ingelheim's serine protease inhibitor, BILN-2061. In small phase I studies, BILN-2061 reduced HCV viral load by 2-3 logs during two days of treatment in people with HCV genotype 1. Despite these promising results, Boehringer Ingelheim has temporarily halted development of BILN-2061, pending evaluation of animal toxicity data. After four weeks of BILN-2061 at much higher doses than those used in humans, monkeys developed cardiac lesions. No similar toxicities have appeared in humans over shorter dosing intervals, though long-term safety data has not been reported.
Two other HCV protease inhibitors have moved into early clinical development. In mid-2004, Vertex will open a phase I study of their HCV serine protease inhibitor, VX-950. According to Vertex's in vitro data, VX-950 is active against HCV that has developed resistance to BILN-2061 (and vice versa, according to BI). Schering has an as yet unnamed HCV protease inhibitor in early phase I research. Other companies are developing HCV serine protease inhibitors, but none has entered testing in humans.
Several other drugs in development are targeting other aspects of HCV replication, such as the HCV RNA-dependent RNA polymerase (roughly analogous to HIV reverse transcriptase). Idenix Pharmaceuticals has an oral HCV polymerase inhibitor, NM283, in phase I/II. A phase I/II trial of Rigel's HCV oral polymerase inhibitor, R803 will open in mid-2004. Japan Tobacco is developing two oral HCV polymerase inhibitors, JTK-109 and JTK-003. In Japan, JTK-003 has moved into phase II; both drugs are in phase I studies outside of Japan. Several other companies have compounds in pre-clinical development.
Other strategies target HCV RNA rather than viral proteins. Antisense oligonucleotides bind to HCV RNA and prevent synthesis of HCV's viral proteins. Isis Pharmaceuticals has developed ISIS-14803, an injectable antisense oligonucleotide. Initial phase II studies have demonstrated safety and efficacy. ISIS-14803 is being evaluated in non-responders to prior HCV therapy with pegylated interferon and ribavirin; trial participants will receive all three drugs.
Hey stranger, how are things going?
That's the spirit!
At the very least you are a responder and probably did your liver some good by treating.
Thanks for your encouragement and I will surely let you know what is next. I am good to hear you were thinking of me and let me tell you I have been thinking of all of you as well.
revenire, Yes there is always good to find. Treatment is never wasted. If you or anyone has any retreatment info please pass it on. I did not do much retreatment research because I expected SVR the first time around.
I saw your posting and hadn't seen you in awhile so was only hoping that it was a continuation of great news! I'm so sorry as you are such a fighter, and strong person! Your previous posts have always been an inspiration. My prayers are with you!!
I don't remember what your original bx result was, what stage were you? What can anyone say about these news, but on with the fight and WE ARE HERE for you.
I am F, 52, also 1a, did not clear at 12wks, did at 24, mild damage, hard not to think that it can happen to any of us, unfortunately.
After a little pity party, then begin to plan what to do next. Maybe two times is a charm.
The fat lady is hanging from my Mardi Gras beads in my Saturn Vue. She was the Saturn beads. I can send her to you so you can shut her up!
best to you